Alpha Cognition Inc
ACOG
Classificação em ações
#20038
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Preço da ação
$8.75
Valor de mercado
$135.82M
Variação (1 dia)
2.88%
Variação (1 ano)
73.86%
País
US
Negociar Alpha Cognition Inc (ACOG)
Categoria
Healthcare
Rácio P/B de Alpha Cognition Inc (ACOG)
Rácio P/B em October 2026 TTM: -114.63
De acordo com os relatórios financeiros mais recentes e o preço das ações da Alpha Cognition Inc, o rácio P/B atual (TTM) é -114.63. No final de 2022, o rácio P/B era -274.94.
Histórico do rácio P/B da Alpha Cognition Inc de 2018 a 2026
Rácio P/B no final de cada ano
| Ano | Rácio P/B | Alterar |
|---|---|---|
| 2026 (TTM) | -114.63 | -53.90% |
| 2023 | -248.67 | -9.55% |
| 2022 | -274.94 | -288.08% |
| 2021 | 146.19 | -97.93% |
| 2020 | 7.05K | 6,164.26% |
| 2019 | 112.47 | 16.25% |
| 2018 | 96.75 | 0.00% |
Rácio P/B de empresas semelhantes ou concorrentes
| Empresa | Rácio P/B | Diferença do rácio P/B | País |
|---|---|---|---|
| 6.251 | -105.45% |
US
|
|
| 13.2547 | -111.56% |
US
|
|
| 4.208 | -103.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -105.39% |
NL
|
